FDA Clears Quidel's Solana MDx Platform, Group A Strep Assay

Jun 23, 2015

|

NEW YORK (GenomeWeb) – Quidel said today that the US Food and Drug Administration cleared the firm's Solana molecular platform and associated Group A Streptococcus assay.

Solana leverages the helicase-dependent amplification technology that also underpins Quidel's AmpliVue molecular technology. Solana can process up to 12 patient samples in a 30-minute run, saving time for healthcare professionals in moderately complex settings, Quidel said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Genes at the Mall Near You?

23andMe has a holiday popup shop at a mall and could open additional stores, Bloomberg reports.

Koalas' Retroviral Response

By studying koalas and a retrovirus that infects them, researchers may have uncovered a new sort of 'immune response' that occurs at the genomic level, Agence France Presse reports.

Bound for Home

NPR reports that the first person in the US given a gene editing-based therapy for a genetic disorder is heading home.

Science Paper Peers into Ancient Social Inequality Within Households

In Science this week: ancient genomes reveal social inequality within individual households, new method for quantifying genetic variation in gene dosage, and more.

Featured White Papers

BlueBee Data Security & Compliance

Menu